🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in Ireland / NCT06906926
Recruiting Not applicable

Harmony TPV EMEA PMS

NCT06906926 · tracked via the Priya Life Science Ireland tracker
Sponsor
Medtronic Cardiovascular
Phase
Not applicable
Started
2025-07-30
Last updated
2026-07-14

Condition(s) studied

Severe Pulmonary Valve Regurgitation

Investigational drug(s) / intervention(s)

Certain imaging assessments can be non-Standard of Care

Certain imaging assessments can be non-Standard of Care: Pre-Implant CT, Chest X-Ray at discharge and any related assessments during the following up visit, can be non-standard of care depending on site's / countries.

Study summary

The Harmony Transcatheter Pulmonary Valve (TPV) System is indicated for use in the management of pediatric and adult congenital heart disease patients with severe pulmonary regurgitation (i.e., severe pulmonary regurgitation as determined by echocardiography and/or pulmonary regurgitant fraction ≥ 30% as determined by cardiac magnetic resonance imaging) who have a native or surgically-repaired right ventricular outflow tract and are clinically indicated for pulmonary valve replacement as judged by the medical team.

Eligibility

Sex
ALL
Min age
Max age
Healthy volunteers
No
Inclusion Criteria: 1. Subject eligible to receive Harmony TPV System in conformity with Instructions for Use (IFU) and local regulations at time of study enrollment. 2. Subject or subject's parent(s)/legal guardian(s) must be willing and able to consent to participate in the study and will commit to completion of all follow-up requirements Exclusion Criteria: 1. Obstruction of the central veins. 2. Planned concomitant branch pulmonary artery stenting at time of implant. 3. Subjects previously treated with an RV-PA conduit or previously implanted bioprosthesis. 4. A major or progressive non-cardiac disease (e.g. liver failure, renal failure, cancer) that results in a life expectancy of less than one year. 5. Planned implantation of the Harmony TPV in the left heart. 6. Echocardiographic evidence of intracardiac mass, thrombus, or vegetation. 7. Pre-existing prosthetic heart valve or prosthetic ring in any position 8. Subject is pregnant as confirmed by a positive pregnancy test before implant procedure for female subjects of childbearing potential. 9. Subjects that are vulnerable as defined in the Section 10.5 Subject Consent Subject Consent Section excerpt: * Vulnerable adults, defined as subjects incapable of giving consent, as assessed per Investigator's opinion and in consideration of vulnerable adult definition per ISO 14155, will not be included in this study. * Any subject with mental incompetence (e.g. Alzheimer's, dementia, psychiatric disorders, developmental disorders, chromosomal abnormalities with associated cognitive impairment) should be assessed by the Investigator for vulnerable status. If pediatric or adult subject is deemed by the Investigator mentally incompetent as described above, the subject will not be included in this study.

Primary outcome measure(s)

Trial sites (12)

FacilityCityRegionStatus
Rigshospitalet Copenhagen Denmark Recruiting
CHU de Bordeaux - Hôpital Cardiologique du Haut-Leveque Bordeaux France Recruiting
Herz - und Diabeteszentrum NRW Bad Oeynhausen Germany Recruiting
Charité - Universitätsmedizin Berlin Berlin Germany Recruiting
Helios Health Institute Standort Leipzig Leipzig Germany Recruiting
TUM University Hospital Munich Germany Recruiting
Mater Misericordiae University Hospital Dublin Ireland Recruiting
Schneider Children's Medical Center Israel Petah Tikva Israel Recruiting
Policlinico di Sant'Orsola Bologna Italy Recruiting
Azienda Ospedaliera di Padova Padova Italy Not Yet Recruiting
Hospital General Universitario Gregorio Marañón Madrid Spain Recruiting
Skånes Universitetssjukhus Lund Lund Sweden Recruiting

More Medtronic Cardiovascular trials in Ireland

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06906926 on ClinicalTrials.gov ↗ ← All trials in Ireland